These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R; Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606 [TBL] [Abstract][Full Text] [Related]
3. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. Lista S; Garaci FG; Ewers M; Teipel S; Zetterberg H; Blennow K; Hampel H Alzheimers Dement; 2014 May; 10(3):381-92. PubMed ID: 23850330 [TBL] [Abstract][Full Text] [Related]
5. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Prvulovic D; Hampel H Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022 [TBL] [Abstract][Full Text] [Related]
6. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773 [TBL] [Abstract][Full Text] [Related]
7. The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis. Szalárdy L; Zádori D; Klivényi P; Vécsei L J Alzheimers Dis; 2016 May; 53(2):373-92. PubMed ID: 27163812 [TBL] [Abstract][Full Text] [Related]
8. Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Engelborghs S Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466 [TBL] [Abstract][Full Text] [Related]
9. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia]. Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ; Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080 [TBL] [Abstract][Full Text] [Related]
10. Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease. Teipel SJ; Sabri O; Grothe M; Barthel H; Prvulovic D; Buerger K; Bokde AL; Ewers M; Hoffmann W; Hampel H J Alzheimers Dis; 2013; 33 Suppl 1():S329-47. PubMed ID: 22735677 [TBL] [Abstract][Full Text] [Related]
11. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: clinical molecular and genetic studies on Alzheimer's disease. Shoji M J Pharmacol Sci; 2012; 118(3):345-9. PubMed ID: 22382661 [TBL] [Abstract][Full Text] [Related]
12. [Defining and disease-modifying therapy for the preclinical stages of Alzheimer's disease]. Sakurai H; Hanyu H Nihon Rinsho; 2016 Mar; 74(3):438-41. PubMed ID: 27025083 [TBL] [Abstract][Full Text] [Related]
13. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease. Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567 [TBL] [Abstract][Full Text] [Related]
14. Biomarkers for preclinical Alzheimer's disease. Tan CC; Yu JT; Tan L J Alzheimers Dis; 2014; 42(4):1051-69. PubMed ID: 25024325 [TBL] [Abstract][Full Text] [Related]
15. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease. Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW; J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335 [TBL] [Abstract][Full Text] [Related]